Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

ClinicalTrials.gov ID: NCT07121192

Public ClinicalTrials.gov record NCT07121192. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a Randomized, Observer-Blind, Study to Evaluate the Immunogenicity and Safety of mRNA-Based Multivalent Seasonal Influenza Vaccine Candidates in Adults 18 Years of Age And Older

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

"The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults."

Study identification

NCT ID
NCT07121192
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
776 participants

Conditions and interventions

Interventions

Biological · Combination Product

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 25, 2025 (Actual)
Primary completion
May 11, 2026 (Actual)
Completion
May 11, 2026 (Actual)
Last update posted
May 28, 2026

2025 – 2026

United States locations

U.S. sites
22
U.S. states
15
U.S. cities
21
Facility City State ZIP Site status
GSK Investigational Site Anniston Alabama 36207 —
GSK Investigational Site Fair Oaks California 95628 —
GSK Investigational Site San Diego California 92120 —
GSK Investigational Site San Diego California 92123 —
GSK Investigational Site Walnut Creek California 94598 —
GSK Investigational Site Hialeah Florida 33012 —
GSK Investigational Site Jupiter Florida 33458 —
GSK Investigational Site Miami Florida 33186 —
GSK Investigational Site Stockbridge Georgia 30281 —
GSK Investigational Site Valparaiso Indiana 46383 —
GSK Investigational Site Lenexa Kansas 66219 —
GSK Investigational Site Springfield Massachusetts 01103 —
GSK Investigational Site Carson City Nevada 89706 —
GSK Investigational Site Rochester New York 14609 —
GSK Investigational Site Greensboro North Carolina 27408 —
GSK Investigational Site Cleveland Ohio 44122 —
GSK Investigational Site North Charleston South Carolina 29405 —
GSK Investigational Site Austin Texas 78705 —
GSK Investigational Site DeSoto Texas 75115 —
GSK Investigational Site Fort Worth Texas 76135 —
GSK Investigational Site Newport News Virginia 23606 —
GSK Investigational Site Seattle Washington 98104 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07121192, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 28, 2026 · Synced Oct 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07121192 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →